Welcome to our dedicated page for Nrx Pharmaceuticals news (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on Nrx Pharmaceuticals stock.
NRx Pharmaceuticals, Inc. reports clinical, regulatory, manufacturing, and subsidiary developments for a biopharmaceutical business focused on neuroplastic therapies for depression, PTSD, suicidality, and related conditions. Company updates center on NRX-100 preservative-free ketamine, NRX-101 as a D-cycloserine/lurasidone fixed-dose combination, FDA communications, generic-drug and new-drug application pathways, and clinical work involving treatment-resistant depression and suicidality.
Recurring news also covers commercial manufacturing preparations, drug-shortage context for ketamine injection, robotic-enabled transcranial magnetic stimulation initiatives through NRx Defense Systems, and interventional psychiatry activity through HOPE Therapeutics. Additional company developments include partnerships involving digital monitoring tools, leadership appointments, and research programs serving military, first-responder, and broader behavioral-health settings.
NRx Pharmaceuticals (Nasdaq: NRXP)/b) highlighted a peer-reviewed poster presented at the 2026 American Society of Clinical Psychopharmacology conference. The Osmind/Yale study used Real World Evidence from 8,224 IV ketamine and 1,830 intranasal esketamine patients with treatment-resistant depression.IV ketamine showed higher remission (34% vs 26%) and response (63% vs 58%) rates, with odds ratios of 1.51 for remission and 1.22 for response. Authors stressed key limitations, including non-randomized treatment assignment and data drawn only from clinics using Osmind’s electronic medical record system.
NRx Pharmaceuticals (Nasdaq: NRXP) closed a public offering of common stock at $3.50 per share, raising approximately $22.3 million in gross proceeds, including the underwriters’ option. The company plans to use net proceeds for working capital and general corporate purposes to support growth.
NRx Pharmaceuticals (Nasdaq: NRXP) priced an underwritten public offering of 5,714,286 common shares at $3.50 per share, targeting approximately $20.0 million in gross proceeds, or $23.0 million if the underwriters’ 30-day option for 857,142 additional shares is fully exercised.
The offering is expected to close on June 4, 2026, subject to customary conditions. Net proceeds are intended for working capital and general corporate purposes to support growth. The deal uses an effective Form S-3 shelf registration statement, with BTIG and Lucid Capital Markets as bookrunning managers.
NRx Pharmaceuticals (Nasdaq: NRXP) plans an underwritten public offering of common stock under its effective Form S-3 shelf registration. The company expects to grant underwriters a 30-day option for up to an additional 15% of shares and intends to use net proceeds for working capital and general corporate purposes.
NRx Pharmaceuticals (Nasdaq: NRXP) announced that strategic partner Emobot Health presented late-breaking pooled clinical validation data for the EMOCARE Depression Thermometer at ASCP 2026.
Across three observational studies, EMOCARE showed within-person concordance with clinician-rated MADRS of r = 0.895 (p = 0.016) and sensitivity to symptom change versus PHQ-9 of ρ = 0.834 (p < 0.001). The smartphone-based, multimodal, passive monitoring tool uses voice, facial expression, motion, and screen behavior to generate continuous depression scores and is being deployed across the Hope Therapeutics interventional psychiatry clinic network as a self-monitoring and safety-net tool.
NRx Pharmaceuticals (Nasdaq: NRXP) announced that subsidiary HOPE Therapeutics is the first commercial site to deploy Zeta Surgical's FDA-cleared Zeta TMS Navigation System at its West Palm Beach clinic.
The AI-guided platform delivers sub-millimetric, image-guided TMS for major depressive disorder and other neurological conditions, supports HOPE's interventional psychiatry network, and aligns with a planned NRX-101 plus robotic-enabled TMS clinical trial in depression and suicidality.
NRx Pharmaceuticals (Nasdaq: NRXP) reported Q1 2026 results and key pipeline advances. Net loss was $1.4 million, versus $5.5 million a year earlier, with operating loss of $4.7 million. Cash was $6.7 million on March 31, 2026, plus about $7 million raised post-quarter via an ATM facility.
NRx advanced its preservative-free ketamine ANDA toward an anticipated FDA decision in Q3 2026 and began commercial-scale manufacturing. It progressed NRX-101 in suicidal bipolar depression and as a TMS adjunct, expanded HOPE Therapeutics clinics, and moved toward acquiring Geneuro Phase 2 HERV-targeted assets.
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, will release its first quarter 2026 financial results before the market opens on Monday, May 18, 2026. Results and a live webcast for the accompanying 8:00 a.m. ET conference call will be available on the company’s investor relations website.
NRx Pharmaceuticals (Nasdaq: NRXP) received FDA clearance to start a randomized, double-blind phase 2/3 trial (MIND1) of NRX-101 (D-cycloserine/lurasidone) versus placebo as an adjunct to robotic-assisted or sham Transcranial Magnetic Stimulation (TMS) in adults with treatment-resistant major depressive disorder and suicidality.
The randomized portion will enroll 240 participants across a US academic hospital and three HOPE Therapeutics sites, with additional participants at two U.S. Military Treatment Facilities; IRB approvals and site details to follow.
NRx Pharmaceuticals (Nasdaq: NRXP) initiated a first commercial GMP manufacturing order for a preservative-free ketamine product ahead of expected GDUFA approval in Summer 2026. The program follows stability from 3 registration batches and a third-party GMP audit; pre-approval inspection readiness is reported.
Manufacturing uses a blow-fill-seal process with >10-fold throughput versus traditional sterile bottling. Company named Glenn Tyson as Chief Commercial Officer and cites ASHP shortage data (April 7, 2026) to underline domestic supply need.